SummitTX Capital’s Lifecore Biomedical LFCR Stock Holding History

SummitTX Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,200	Closed	-$114K	–	901
2025 Q1	$114K	Buy	+16,200	New	+$101K	﹤0.01%	752

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

SummitTX Capital's LFCR Position: Q2 2025 in Review

SummitTX Capital sold out of Lifecore Biomedical (LFCR) in Q2 2025, closing a stake of 16,200 shares — an estimated $114K sold.

SummitTX Capital first reported a position in LFCR in Q1 2025 and held it in 1 quarter. The position peaked at $114K in Q1 2025. 86 funds tracked by Wall St. Rank hold LFCR as of Q2 2025.

SummitTX Capital reported no remaining Lifecore Biomedical position as of Q2 2025 after selling out during the quarter.
SummitTX Capital sold 16,200 Lifecore Biomedical shares in Q2 2025, an estimated $114K.
SummitTX Capital first reported a position in Lifecore Biomedical in Q1 2025 and held it in 1 quarter.
SummitTX Capital's Lifecore Biomedical position peaked at $114K in Q1 2025.
86 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2025.

Based on SummitTX Capital's 13F filing for Q2 2025, filed 14 Aug 2025.